Drugs / Lebrikizumab
Lebrikizumab
also known as
LY3650150 · MILR1444A · LEB · Ebglyss · Lebrikizumab-lbkz · PRO-301444 · PRO-301444 RG-3637 · RO-5490255 · +1 more
Monoclonal antibody targets IL13
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Ebglyss | — | 2023-11-16 | europa.eu ↗ |
Trials 45 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06243198 | Mar → Sep 2024 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04840901 | Jun 2021 → Feb 2022 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01423318 | Aug 2011 → Feb 2012 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00441818 | May 2006 → Jun 2007 | Hodgkins lymphoma | Tanox | Unknown | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT07620561 | Jun 2026 → Dec 2027 expected | prurigo nodularis | University of Maryland, Baltimore | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03443024 | Jan 2018 → Feb 2019 | atopic eczema | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT02546700 | Sep 2015 → Nov 2016 | chronic obstructive pulmonary disease | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT02465606 | Jul 2015 → May 2016 | atopic eczema | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT02340234 | May 2015 → Apr 2016 | atopic eczema | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT02099656 | Nov 2014 → Oct 2016 | asthma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01987492 | Feb 2014 → Dec 2016 | asthma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01872689 | Oct 2013 → Jul 2017 | idiopathic pulmonary fibrosis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01545440 | Mar 2012 → Mar 2013 | asthma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01545453 | Mar 2012 → Jul 2013 | asthma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00971035 | Nov 2009 → Dec 2010 | asthma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00930163 | Jul 2009 → Jul 2010 | asthma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00781443 | Dec 2008 → Nov 2009 | allergic asthma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 325 trials | ||||||
| Phase 3 | NCT07542483 | Apr 2026 → Aug 2028 expected | — | Almirall, S.A. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06921759 | Apr 2025 → May 2026 overdue | atopic eczema | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06526182 | Jul 2024 → Apr 2027 expected | atopic eczema | Almirall, S.A. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06338995 | Apr 2024 → May 2027 expected | chronic rhinosinusitis | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06339008 | Apr 2024 → Sep 2026 expected | perennial allergic rhinitis | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06280716 | Apr 2024 → Sep 2025 overdue | atopic eczema | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05990725 | Nov 2023 → Jun 2025 | atopic eczema | Almirall, S.A. | Completed | No outcome recorded |
| Phase 3 | NCT05916365 | May 2023 → Apr 2026 | atopic eczema | Almirall, S.A. | Completed | No outcome recorded |
| Phase 3 | NCT05735483 | Mar 2023 → Dec 2027 expected | atopic eczema | Eli Lilly and Company | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05372419 | Jan 2023 → May 2024 | atopic eczema | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05369403 | Dec 2022 → Jan 2024 | atopic eczema | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05559359 | Oct 2022 → Jan 2026 overdue | atopic eczema | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05149313 | Dec 2021 → Jan 2023 | atopic eczema | Almirall, S.A. | Completed | No outcome recorded |
| Phase 3 | NCT04760314 | Mar 2021 → Jul 2022 | atopic eczema | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04626297 | Nov 2020 → Aug 2022 | atopic eczema | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04392154 | Jun 2020 → Jul 2024 | atopic eczema | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04250350 | Feb 2020 → Apr 2022 | atopic eczema | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04250337 | Feb 2020 → Aug 2021 | atopic eczema | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04178967 | Oct 2019 → Jul 2021 | atopic eczema | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04146363 | Sep 2019 → Jun 2021 | atopic eczema | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02546869 | Sep 2015 → Jun 2016 | asthma | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 3 | NCT02104674 | Jun 2014 → Jan 2016 | asthma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01875003 | Aug 2013 → Dec 2016 | asthma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT01868061 | Jul 2013 → Jan 2017 | asthma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01867125 | Jul 2013 → Dec 2016 | asthma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07352566 | Aug 2026 → Jun 2030 expected | atopic eczema, psoriasis | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06906497 | Jul 2025 → Jul 2027 expected | atopic eczema | Johann E Gudjonsson MD PhD | Recruiting | No outcome recorded |
| Phase 4 | NCT07006792 | Jun 2025 → May 2026 overdue | atopic eczema | Eli Lilly and Company | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07471932 Comparator | Feb 2026 → May 2027 expected | — | Almirall, S.A. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06444165 Background | Jun 2024 | atopic eczema | Eli Lilly and Company | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-02-29 | Roche Global Development | Roche provides update on two identical phase III studies of lebrikizumab in people with severe asthma roche.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 51 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lebrikizumab | “A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)” NCT06338995 ↗45“A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)” NCT06339008 ↗ |
| Known as | Ebglyss | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743035 ↗ |
| Known as | LEB | “Lebrikizumab (LEB), a high-affinity monoclonal antibody targeting interleukin (IL)-13” PMID 36630140 ↗ Feb 20231“lebrikizumab (LEB) 250 mg Q2W, Q4W, or placebo” PMID 42315763 ↗ Jun 2026 |
| Known as | Lebrikizumab-lbkz | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743035 ↗ |
| Known as | LY3650150 | “A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/ LY3650150 in Adult Participants...” NCT06339008 ↗2“A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)” NCT06338995 ↗ “A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants” NCT04840901 ↗ |
| Known as | MILR1444A | “Drug: lebrikizumab (MILR1444A)” NCT00971035 ↗ |
| Known as | PRO-301444 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743035 ↗ |
| Known as | PRO-301444 RG-3637 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743035 ↗ |
| Known as | RO-5490255 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743035 ↗ |
| Known as | TNX-650 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00441818 ↗ |
| Action | Inhibit | “IL13 pathway inhibition” PMID 24131304 ↗ Jan 2014 |
| Modality | Monoclonal antibody | “an anti-IL13 monoclonal antibody” PMID 24131304 ↗ Jan 2014 |
| Route | Subcutaneous | “administered subcutaneously” PMID 24131304 ↗ Jan 2014 |
| Target | IL13 | “anti-IL13 monoclonal antibody” PMID 24131304 ↗ Jan 2014 |